Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138525 · ClinicalTrials.gov registry record
Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 161
- Enrollment target
NCT03138525: Completed study, sponsored by Brigham and Women's Hospital.
NCT03138525 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03138525 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
Study Summary
The purpose of this study is to assess effects of B cell depletion on the immune system in patients with relapsing forms of multiple sclerosis (MS) treated with ocrelizumab. This will be done by collecting blood from patients starting treatment with ocrelizumab before the first infusion and before the infusions at 6 and 12 months. The effects on the immune system will be assessed by performing transcriptome profiling of immune cells, measuring serum levels of microRNAs, and analyzing serum autoantibody immune signatures using antigen arrays. In addition, blood will be collected once from a group of healthy individuals to serve as controls.
Primary Outcome
Changes in messenger ribonucleic acid (mRNA) expression
Interventions
- OTHER Blood sampling (MS)
- OTHER Blood sampling (controls)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2017-06-20 |
| Est. Completion | 2019-12-20 |
What the finished NCT03138525 record still lists
NCT03138525 is an observational study that tracks outcomes without assigning an intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Blood sampling (MS) is the first listed.
NCT03138525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03138525 about?
NCT03138525 is a clinical study titled "Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis". The purpose of this study is to assess effects of B cell depletion on the immune system in patients with relapsing forms of multiple sclerosis (MS) treated with ocrelizumab. This will be done by collecting blood from patients starting treatment with ocrelizumab before the first infusion and before t...
What is the current status of trial NCT03138525?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2017-06-20. Estimated completion is 2019-12-20.
What interventions are being tested in trial NCT03138525?
The interventions under investigation include: Blood sampling (MS) (OTHER), Blood sampling (controls) (OTHER).
Who is sponsoring clinical trial NCT03138525?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI